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ABSTRACT
Objective: There has been considerable interest in the
impact of reproductive factors on health but there are
little data on how these have varied over time. We
explore trends in reproductive/lifestyle factors of
postmenopausal British women by analysing self-
reported data from participants of the UK Collaborative
Trial of Ovarian Cancer Screening (UKCTOCS).
Design: Prospective birth cohort analysis.
Setting: Population cohort invited between 2001 and
2005 from age-sex registers of 27 Primary Care Trusts
in England, Wales and Northern Ireland and recruited
through 13 National Health Service Trusts.
Participants: 202 638 postmenopausal women aged
50–74 years at randomisation to UKCTOCS between
April 2001 and October 2005.
Interventions: Women were stratified into the
following six birth cohorts (1925–1929, 1930–1934,
1935–1939, 1940–1944, 1945–1949, 1950–1955)
based on year of birth. Self-reported data on
reproductive factors provided at recruitment were
explored using tabular and graphical summaries to
examine for differences between the birth cohorts.
Outcome measures: Trends in mean age at
menarche and menopause, use of oral contraceptives,
change in family size, infertility treatments, tubal
ligation and hysterectomy rates.
Results: Women born between 1935 and 1955 made
up 86% of the cohort. Median age at menarche
decreased from 13.4 for women born between 1925
and 1929 to 12.8 for women born between 1950 and
1955. Increased use of the oral contraceptives,
infertility treatments and smaller family size was
observed in the younger birth cohorts. Tubal ligation
rates increased for those born between 1925 and
1945, but this increase did not persist in subsequent
cohorts. Hysterectomy rates (17–20%) did not change
over time.
Conclusions: The trends seen in this large cohort are
likely to reflect the reproductive history of the UK
female postmenopausal population of similar age.
Since these are risk factors for hormone-related
cancers, these trends are important in understanding
the changing incidence of these cancers.
Trial registration number: International Standard
Randomised Controlled Trial Number: 22488978.
INTRODUCTION
In recent years, there has been increasing
interest and mounting evidence on the long-
term impact of reproductive and lifestyle
factors on health, especially cancer, cardio-
vascular disease and overall mortality.1 The
main focus has been oral contraceptives use,
hormone replacement therapy (HRT), parity
and breastfeeding.2–4 There are, however,
little data examining how these factors have
varied over time.
During the 20th century, data from the
USA showed an increase in the reproductive
lifespan of women from 36.1 years for those
Strengths and limitations of this study
▪ Largest birth cohort analysis to report on trends
in reproductive and lifestyle factors.
▪ Over 25 000 women in each of the birth cohorts
barring the earliest.
▪ Women born between the 1920s and 1950s
were invited from population age-sex registers
rather than self-referral.
▪ High-quality self-reported data on reproductive
and lifestyle factors.
▪ Key limitations were that women were likely to
be more health-conscious as they agreed to par-
ticipate in a screening trial and a lack of details
such as oral contraceptives formulation and type
of infertility treatment.
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born between 1915 and 1919 to 37.7 years for those
born between 1935 and 1939 as a result of earlier
menarche and later menopause.5 A decline in age at
menarche from 13.5 years in those born between 1908
and 1919 to 12.6 for those born between 1945 and 1949
has also been reported from the UK.6 Oral contracep-
tives use has increased in Europe7 and the USA8 and
this has been accompanied by a decline in tubal ligation
rates in the USA9 and Scandinavia.10 More recently,
there have been reports from Italy, Australia and the UK
on a reduction in hysterectomy rates over the past
decade.11–13 All of these factors most likely affect a
woman’s lifetime exposure to circulating endogenous
hormones and ultimately future disease/cancer burden.
In this paper, we report on trends in reproductive and
lifestyle factors in British women born between 1925 and
1955 by undertaking a birth cohort analysis of partici-
pants in the UK Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS).
METHODS
Study population and data collection
UKCTOCS is a randomised controlled trial designed to
assess the impact of screening on ovarian cancer mortal-
ity. Between April 2001 and October 2005, 1.2 million
women born between 1925 and 1955 were randomly
invited from the age-sex registers of 27 participating
primary care trusts. Women had to be postmenopausal
(deﬁned as either >12 months amenorrhoea following a
natural menopause or hysterectomy, or >12 months of
hormone replacement therapy started for menopausal
symptoms) in addition to being aged 50–74 years at
recruitment. Exclusion criteria included bilateral
oophorectomy, previous ovarian malignancy, increased
risk of familial ovarian cancer, active non-ovarian malig-
nancy and participation in other ovarian cancer screen-
ing trials. A total of 288 955 agreed to participate in the
trial and 202 638 eligible postmenopausal women were
ﬁnally recruited through 13 regional trial centres
located in National Health Service Trusts in England,
Wales and Northern Ireland.14 The trial design, includ-
ing details of recruitment and randomisation, has been
described in detail elsewhere, which also included the
detailed CONSORT diagram.14 All women provided
written consent.
At recruitment, all women completed an 18-item ques-
tionnaire. The recruitment questionnaire (see online
supplementary data, appendix 1) captured data on
demographics (ethnicity), reproductive factors (age at
menarche, previous oral contraceptives use and dur-
ation, age at menopause), gynaecological procedures
(tubal ligation, hysterectomy with ovarian conservation)
and parity (number of pregnancies <6 months which
included miscarriages, abortions and ectopic pregnan-
cies; number of pregnancies lasting over 6 months) and
infertility treatment. Age at menopause was derived
from age at last period excluding those who had
self-reported hysterectomy at recruitment with a sub-
group analysis excluding those who reported HRT use at
recruitment. Personal history of cancer and family
history of breast or ovarian cancer were also captured.
For the purposes of this analysis, the women were
grouped according to year of birth into the following six
cohorts: 1925–1929, 1930–1934, 1935–1939, 1940–1944,
1945–1949 and 1950–1955. In a subset of 144 454
women who answered a postal follow-up questionnaire
3–5 years postrandomisation, information on education
was also available.
Statistical analysis
Extreme biometric data values, which were almost cer-
tainly errors, were discarded to protect the analyses from
their undue inﬂuence on statistical methods for continu-
ous data. The data were logged and values that were
more than 5 SDs from the mean were discarded. The
mean and SD were then recalculated. This threshold
rule was applied one more time using the recalculated
summary statistics, before anti-logging the data back to
the original metric. While this removed distorting
values, it may also have excluded some genuine values
that were simply extreme outliers as it was based on a
statistical rule of deviation from the mean rather than a
judgement on what constitutes an erroneous value.
Trends and differences in baseline characteristics such
as age at menarche, age at menopause, oral contracep-
tives use, hysterectomy, tubal ligation, infertility treat-
ment and parity were explored using tabular and
graphical summaries with 95% CIs added to the latter.
Formal tests for trends were not considered, as the trend
was not linear for most variables. In addition, the large
sample size resulted in almost all pairwise cohort-
comparisons for each variable being highly signiﬁcant
even when adjusted for multiple comparisons.
RESULTS
The data captured at recruitment were available for
202 637 women as one woman asked for all her personal
identiﬁers and associated data to be removed from the
UKCTOCS database. All women were postmenopausal.
The median age at completion of the baseline question-
naire (age at randomisation) was 60.6 (IQR 55.9–66.2).
Demographics
Except for the oldest birth cohort (1925–1929), each of
the remaining ﬁve cohorts included a minimum of
25 000 women (table 1). The majority (96.4%; 195 275)
were white. When the women were separated into birth
cohorts, there was an increase in the percentage of
non-Caucasians in the younger compared to the oldest
cohorts. However, it must be noted that the numbers in
these groups were small (data not shown). About 40.0%
of women in the oldest (1925–1929) cohort reported no
formal educational qualiﬁcation compared with 19.1%
in the youngest birth cohort. This was paralleled by a
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rise in those with a college/university degree from
14.6% (1925–1929) to 29.5% (1950–1955) (data not
shown). About 6.0% had a personal history of cancer
with breast cancer being the most common (table 1).
Menarche and menopause
The mean age at menarche decreased signiﬁcantly from
13.4 years for women born between 1925 and 1929
to 12.8 years for those born between 1950 and 1955
(ﬁgure 1A, see online supplementary data, appendix 2,
supplementary table S1). The mean age at natural
menopause (women who had hysterectomy at recruit-
ment were excluded) for the cohort was 50.3 years (SD
4.32). On sensitivity analysis limited to those not using
HRT at recruitment, the mean age at natural menopause
was 50.1 years (SD 5.05). The mean age of natural
menopause increased from 49.5 years for women born
between 1925 and 1929 to 50.7 years for the 1940–1944
birth cohort (ﬁgure 1B, see online supplementary data,
appendix 2, supplementary table S1) but then decreased
to 48.7 years for the youngest birth cohort. Similar
trends were observed when women on HRT were
excluded.
Contraception and gynaecological procedures
Increased oral contraceptives use was reported by
younger birth cohorts with the highest use of 85.3% in
women born between 1950 and 1955 (ﬁgure 1C, see
online supplementary data, appendix 2, supplementary
table S1). The mean duration of oral contraceptives use
increased from 6.2 years in those born between 1925
and 1929 to 7.9 years in the younger cohorts (1950–
1955) (ﬁgure 1D, see online supplementary data,
appendix 2, supplementary table S1). Overall, 18.9%
(38 211) of women underwent hysterectomy with
ovarian conservation, with the highest rate of 20.2% in
women born between 1935 and 1939 (ﬁgure 2A, see
online supplementary data, appendix 2, supplementary
table S1).
Parity and infertility
The overall proportion of women having a viable
(lasting over 6 months) pregnancy was 88.4% and
remained unchanged between the birth cohorts (see
online supplementary data, appendix 2, supplementary
table S1). Family size based on number of viable preg-
nancies decreased across birth cohorts. Fewer women
had four or more pregnancies lasting over 6 months in
the younger (7.5%) when compared to the older
(16.6%) cohorts while those having one or two pregnan-
cies increased (47.0% and 58.2%, respectively) (ﬁgure
2B, see online supplementary data, appendix 2,
supplementary table S1).
The proportion of women who had never conceived
(nulligravid) ranged from 8.5% to 11.6% and showed an
obvious quadratic trend (ﬁgure 2B, see online
supplementary data, appendix 2, supplementary table S1).
This was despite a 5.5-fold increase in self-reported infertil-
ity treatment, which increased from 1.1% (of women born
between 1925 and 1929) to 6.1% (of those in the 1950–
1955 cohort) (ﬁgure 2C, see online supplementary data,
appendix 2, supplementary table S1). The percentage of
nulligravid women who had availed of infertility treatment
Table 1 Baseline characteristics of the UKCTOCS cohort
Number of
women Per cent
Birth cohort
1925 to 1929 2588 1.3
1930 to 1934 26 201 12.9
1935 to 1939 41 418 20.4
1940 to 1944 51 057 25.2
1945 to 1949 55 510 27.4
1950 to 1955* 25 863 12.8
Ethnicity
Caucasian 195 275 96.4
Black 2769 1.4
Asian 1856 0.9
Other 1695 0.8
Missing data 1043 0.5
Cancer history
Personal history of cancer 12 060 6.0
Breast 7652 3.8
Bowel 760 0.4
Lung 100 0.1
Other 3548 1.8
Maternal history of cancer
Maternal history of breast/
ovarian cancer
16 025 7.9
Breast 12 990 6.4
Ovarian 3162 1.5
Both 127 0.1
Family history of breast or ovarian cancer
Family history of ovarian
cancer
9184 4.5
Number of relatives with ovarian cancer
1 9028 0.1
2 142 0.1
>2 14 0
Family history of breast cancer 45 010 22.2
Number of relatives with breast cancer
1 36 965 18.2
2 6460 3.2
>2 1585 0.8
BMI
Underweight (<18.5) 1874 0.9
Normal (18.5–24.9) 83 062 41
Overweight (25.0–29.9) 74 283 36.7
Obese (>30) 41 236 20.3
Education†
College/University or equivalent 29 428 20.2
Other formal education 69 862 48.4
No formal educational
qualification
41 666 28.8
Missing data 3498 2.4
*Includes 370 women born in 1955
†Subcohort analysis of 144 454 from a follow-up questionnaire
BMI, body mass index; UKCTOCS, UK Collaborative Trial of
Ovarian Cancer Screening.
Gentry-Maharaj A, et al. BMJ Open 2017;7:e011822. doi:10.1136/bmjopen-2016-011822 3
Open Access
Figure 1 Trends in (A) age at menarche, (B) age at menopause, (C) ever use of oral contraceptives and (D) duration of oral
contraceptives use in oral contraceptive users.
Figure 2 Trends in (A) hysterectomy rates between the birth cohorts (B) parity (pregnancies >6 months; includes those who
had at least one pregnancy <6 months but had no pregnancy >6 months red line and those who were nulligravid purple line),
(C) those seeking infertility treatment, (D) tubal ligation rates between the birth cohorts.
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increased from 1.0% of those born between 1925 and
1930 to 11.5% of women born between 1945 and 1950
(data not shown). Tubal ligation rates peaked at 24.6% in
those born between 1940 and 1944 compared with only
6.0% of the women born between 1925 and 1929 undergo-
ing the procedure (ﬁgure 2D, see online supplementary
data, appendix 2, supplementary table S1).
DISCUSSION
Main findings
To the best of our knowledge, this is the largest birth
cohort analysis to report on trends in reproductive and
lifestyle factors in women born between the 1920s and
1950s. We found that in the UK, family size decreased in
younger birth cohorts accompanied by an increase in
oral contraceptives use. The initial increase in uptake of
tubal ligation was not sustained. For women born
between 1925 and 1955, increasing use of infertility treat-
ments was not accompanied by a change in the propor-
tion of nulligravid women. The hysterectomy rates were
similar across the cohorts. Finally, we observed a decrease
in the mean age at menarche. These changing trends
directly contribute to a woman’s exposure to endogen-
ous and exogenous oestrogen and are likely to inﬂuence
the incidence of hormonally dependent cancers.
Strengths and limitations
A major strength is the overall size with over 25 000
women in each birth cohort except the earliest. Instead
of self-referral, one in six women aged 50–74 years in
the general population was randomly chosen from
age-sex registers and sent a personal invitation to partici-
pate.14 While a healthy volunteer effect was noted in the
cohort early on,15 this was not pronounced at the end of
the trial with the mortality rate ratio between the control
and screening arms being 0.99 for overall deaths and
1.00 for cancers other than ovarian/peritoneal.16 While
the analysis is dependent on self-reporting which is
affected by recall bias, especially in older women, the
validity of self-reporting of these variables has been pre-
viously described in the literature17–21 including valid-
ation of self-reported hysterectomy in this cohort.18
Scanning and checking of data entry reduced transcrip-
tion error while the limited extent of missing data
ensured that such records could be discarded without
concern of bias. Furthermore, a strength of our data is
that the narrowness of the CIs resulting from such a
large sample means that any notable change in trend
could be interpreted as a real difference and not
random perturbation of the data.
A limitation is that this cohort consists of women who
wished to participate in a randomised controlled trial of
ovarian cancer screening. As a result, they are likely to
be more health-conscious.22 About 96.4% were white
compared with 92.1% in the 2001 census.23 Additionally,
we only captured limited data at recruitment and the
need to keep the questionnaire brief meant that no
details regarding oral contraceptives formulation, details
of infertility treatment, age at childbirth or duration of
breastfeeding were captured.
Interpretation
The mean age at menarche decreased from 13.4 years
for women born between 1925 and 1929 to 12.8 years for
those born in the later cohorts (1950–1955), which is
comparable to a recent British study, showing a decline
in the mean age at menarche from 13.5 years for women
born between 1908 and 1919 to 12.6 years for those born
between 1945 and 1949.6 Other studies have similarly
reported a decline.5 24 The mean age of natural meno-
pause was 50.1 years for non-HRT users, which is similar
to that reported for Western countries.25 We did not
observe an increase in the mean age at menopause as
previously reported.5 26–28 The two together are major
determinants of endogenous hormone exposure, which
is associated with osteoporosis, heart disease and cancer
risk, as well as all-cause mortality.1 4 29 Early age at
menarche has been linked to increased risk of breast,
endometrial and ovarian cancer.3 30 31 A recent
meta-analysis of over 100 000 women showed that the
risk of breast cancer increased by lengthening of a
woman’s reproductive years and early menarche played a
greater role than later menopause.30 While the women
in the younger birth cohorts in our study had a lower
age at menopause, this could be the result of the trial eli-
gibility criteria that required women to be postmenopau-
sal rather than a real effect of decrease in age at
menopause in this group of women. It is possible that
the length of the reproductive period may be a more
important factor in predisposing a woman to risk of
hormone-related cancers. Similar trends of earlier
menarche and decrease in family size have also been
reported for a large cohort of Chinese women.32
Oral contraceptives use was highest among women in
the 1950–1955 cohort with 85% reporting ever use. Since
the ‘pill’ was only discovered in the 1950s and approved
for contraceptive use in the UK in 1961, women in the
later birth cohorts may have had easier access to it. More
importantly, changing social norms made its use more
acceptable. By 1970, negative publicity surrounding the
potential risks (mainly thrombosis) published in various
British medical journals and newspapers may have inﬂu-
enced womens’ decision against the use of oral contra-
ceptives.33 However, we did not observe an impact within
our cohort, as oral contraceptives use increased steadily.
Overall, 60% had reported ever use, which is identical to
the percentage of oral contraceptive users reported from
the Million Women Study. A recent large US study on
oral contraceptives and mortality found the prevalence
of oral contraceptives use to be 48%, but the limitation
of the US study is that it only included married women
between the ages of 30–55 years.2
The increase in tubal ligation rates for women born
until 1945 likely reﬂects the availability of the procedure
and is most likely inﬂuenced by the change in
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ambulatory settings (inpatient to outpatient). However,
the subsequent plateau may reﬂect increasing availability
of other effective options for contraception. Overall,
19% underwent hysterectomy with conservation of at
least one ovary. This is in keeping with a 20% hysterec-
tomy rate at median age 60 years reported by a UK study
which reported that most of these women had under-
gone the procedure for benign conditions in their
mid-40s.34 The UKCTOCS rates do not include hysterec-
tomies where both ovaries were removed as such women
were ineligible to participate. This may explain the lower
rates compared with 25.1% noted in the Million Women
Study. About 7.4% of women in the latter cohort had
undergone bilateral oophorectomy.35 There were small
ﬂuctuations in hysterectomy rates across the birth
cohorts, which most likely relate to changing attitudes to
ovarian conservation during hysterectomy and increas-
ing trends in conservative management of dysfunctional
uterine bleeding and ﬁbroids.
There was a trend towards larger families in those
born prior to 1940 in keeping with the postwar era in
the UK (1945–1950) which saw sharp peaks in the total
fertility rate during the 1960s Baby Boom.36 This was
when women in the 1930–1940 cohorts were of child-
bearing age. Later cohorts tended to have two children,
reﬂecting increased availability of family planning
methods, especially oral contraceptives and changing
social attitudes towards female education and employ-
ment. Women seeking infertility treatment increased
steadily in later birth cohorts as previously reported.37
This possibly reﬂects the increasing availability of infertil-
ity treatments. Despite this, the proportion of women
who never conceived remained static across the birth
cohorts, as success rates were low prior to introduction
of in vitro fertilisation and embryo transfer.38
The changes described in reproductive and lifestyle
factors are likely to contribute to changing incidence in
hormone-related cancers such as breast, endometrial
and ovarian cancer. For ovarian cancer, for example,
incidence rates in Great Britain have increased by 28%
between 1979–1981 and 1997–1999 and then decreased
by 8%.39 To forecast impact, statistical modelling needs
to take into account both factors that decrease incidence
such as increasing oral contraceptives use in younger
birth cohorts as well as those that increase incidence
such as smaller families, earlier menarche, late meno-
pause and increasing life expectancy.
CONCLUSION
There were clear differences in the reproductive factors
across birth cohorts in the UK, with later birth cohorts
reporting a lower age of menarche, smaller family size
and increased use of oral contraceptives and infertility
treatments and a decrease in the age at menopause in
those born after 1945. While the absolute rates cannot
be extrapolated to the general population, the trends in
this large cohort of women, although inﬂuenced by a
‘healthy volunteer effect’, most likely represent trends
in the UK population. The changes in lifetime sex
hormone exposure resulting from these changes could
in part explain the trends in breast, endometrial and
ovarian cancer incidence as well as other diseases such
as osteoporosis, heart disease and neurodegenerative dis-
orders. Further exploration of these trends could
explain their more precise contribution to both disease
incidence and mortality.
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